Prima v1.0
PRIMA is a radiation-free, AI-ready 3D scanning device that uses cameras and edge detection to monitor Hand Osteoarthritis progression with ±0.1 mm accuracy in just 10 seconds.

PRIMA is a radiation-free 3D scanning device designed to quantitatively monitor Hand Osteoarthritis (OA) progression in clinical settings. The scanner is composed of cameras attached to a semi-circular ring which acquires pictures of a finger from different angles, combined with LED strip lighting for uniform illumination. Using edge detection algorithms, the system generates a 3D reconstruction of individual hands/fingers, enabling clinicians to track morphological changes such as Heberden's and Bouchard's nodes over time.
AI-Integrated Features: PRIMA is designed as an AI-ready platform with integrated capabilities for advanced diagnostics:
Predictive Analytics: The system is architected to support machine learning algorithms for automated disease progression forecasting based on longitudinal 3D scan data
Automated Reporting: AI-powered analysis can generate objective diagnostic reports, reducing interpretation variability between clinicians
Cloud Storage & AI Analytics Subscription: Optional cloud-based service enabling secure patient data storage, cross-institutional comparison, and continuous model improvement through incremental machine learning
The software architecture follows IMDRF guidelines for Machine Learning Software (Incremental)—software that continuously uses input data to extend its knowledge after market release
Key Technical Specifications:
Scan time: 10.3 ± 0.7 seconds per hand/finger
Repeatability: coefficient of variation < 1.3%
Clinical Value: Unlike current X-ray imaging methods that expose patients to harmful radiation and require specialist clinicians, PRIMA offers a safe, non-invasive alternative suitable for use by general practitioners in clinics and GP studios. The device outputs key physiological parameters—including DIP joint-to-phalanx diameter ratios and phalangeal deviation angles—providing objective, quantitative data to support diagnosis and treatment planning for the 8.75 million people over 45 who have sought treatment for OA.